Researchers used reverse genetics to generate a recombinant feline calicivirus (FCV) in which the small, bright luciferase NanoLuc was inserted into the LC protein of the FCV Urbana backbone, creating FCV-UrbanaNL. The reporter construction was intended to provide a sensitive, quantitative readout of viral replication that can be measured by luciferase activity, facilitating higher-throughput virological assays compared with traditional plaque-based or cytopathic effect readouts.
Details of the cloning strategy, insertion site validation, and rescue of infectious reporter virus were provided in the original study; the summary here does not include the step-by-step molecular methods or sequence boundaries.
The authors characterised the replication kinetics of FCV-UrbanaNL relative to its parental FCV-Urbana strain to assess whether NanoLuc insertion altered viral growth. They also assessed the genetic and phenotypic stability of the reporter over multiple passages to determine whether luciferase expression persisted during routine propagation.
The source report indicates comparative characterisation was performed, but the abstracted summary does not include quantitative growth curves, timepoints, or passage numbers. Where such specifics are required for assay validation or biosafety considerations, readers should consult the full preprint for experimental detail.
Using FCV-UrbanaNL, the team developed luciferase-based virus neutralisation assays to evaluate neutralising activity of a panel of monoclonal antibodies that recognise the FCV Urbana strain. The NanoLuc signal provided a direct, quantitative measure of infection inhibition, enabling assessment of antibody potency in a reproducible assay format.
This reporter-based neutralisation approach is positioned as a tractable alternative to more labour-intensive neutralisation tests. The summary does not list individual monoclonal antibodies, their epitopes, or neutralisation titres; those data are available in the full manuscript.
To probe how capsid variation affects neutralisation, the investigators engineered chimeric reporter viruses by exchanging the major capsid protein VP1 of FCV Urbana with VP1 sequences from two alternative strains: the vaccine strain F9 and a virulent systemic strain NSW‑E1. These VP1-swapped reporter viruses were then used in neutralisation assays to compare how antibody recognition and neutralising potency varied with capsid origin.
This approach allows direct testing of cross-neutralisation between vaccine, laboratory, and virulent systemic strains in an isogenic background, isolating the contribution of VP1 to antigenicity and neutralisation sensitivity.
The FCV-UrbanaNL reporter system was applied to screen candidate antiviral compounds. Using this platform, the authors identified GS-441524—the active metabolite of remdesivir—as having therapeutic potential against FCV in the reporter assay format. The abstracted summary reports identification of GS-441524 as an active compound but does not provide dose–response parameters, cytotoxicity measures, or in vitro selectivity indices; these experimental details are in the underlying preprint.
The luciferase reporter permits rapid, quantitative assessment of antiviral efficacy and can accelerate prioritisation of small molecules for further in vitro and in vivo evaluation.
The study demonstrates that a NanoLuc-expressing FCV can serve as a versatile molecular tool to accelerate the development and evaluation of immunotherapeutics and small-molecule antivirals against feline calicivirus. Advantages include sensitive luminescence readouts, suitability for neutralisation assays, and the ability to test capsid-swapped variants to probe antigenic breadth.
Limitations noted in the summary: precise replication kinetics, numerical neutralisation and antiviral potency data, and detailed methods (e.g., passage numbers, antibody identities, compound screening conditions) were not reported in the article abstract. For implementation in diagnostic or regulatory contexts, full experimental datasets, reproducibility metrics, and biosafety considerations should be reviewed in the complete preprint.
Collectively, these findings support the utility of FCV-UrbanaNL as a platform for rapid screening of vaccine candidates, monoclonal antibodies, and antiviral compounds, and present GS-441524 as a candidate for further evaluation against FCV in detailed in vitro and in vivo studies.